Business news: Elsevier, FDA

Share this article:
Elsevier launched a new title: the Journal of Behavioral Sciences. The publication is the official journal of the Association for Contextual Behavioral Science. “It has been a long time in the making,” ACBS president-elect Sonja Batten said in a statement. The quarterly's first issue printed in December and is available on ScienceDirect.

FDA is looking into opioids and chronic pain and has scheduled a two-day public hearing, beginning February 7. Each seven-hour session will be held in Bethesda, MD, and will address questions that include what methods professionals currently use to distinguish types of pain, how they differentiate chronic from short-term pain and if there is data that would support or oppose implementing maximum daily doses. The drug category came under periodic scrutiny in 2012, a review which included the outing of an industry-funded pain-pill advocacy group for recommendations lacking scientific bases, as well as CDC research that indicates prescription painkillers, both opioid and non, are linked to 75% of prescription drug overdoses. The CDC also reports that about 2 million people first used prescription painkillers for nonmedical reasons in 2010. This comes down to approximately 5,500 first-time non-medical users a day. The FDA issued draft guidance earlier this month that proposes drug makers test a drug's abuse potential by evaluating the benefits of bypassing abuse-deterrent measures through crushing, grinding or melting the product or how a formulation could make extracting the opiates difficult and thereby limit its desirability for intravenous injection.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions